Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canrenone in Moderate to Severe COVID-19 ARDS
NCT04977960Phase 2Unknown
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of potassium canrenoate in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Status: unknown.
02
Drugs
potassium canrenoate
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04977960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977960.